Pyxis Oncology Reports Third Quarter 2026 Financial Results and Highlights Progress Toward Pivotal Development of Micvotabart Pelidotin (MICVO)
Milestone-linked warrants could provide approximately $172.6 million in additional gross proceeds if exercised in full for cash.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Pyxis Oncology (Nasdaq: PYXS) reported a narrower third-quarter 2026 net loss while advancing plans for pivotal development of MICVO in head and neck cancer. Net loss was $19.984 million, or $0.24 per share, versus $22.003 million, or $0.35 per share, a year earlier.
Updated Phase 1 monotherapy results showed a 36% confirmed response rate in 33 efficacy-evaluable patients and median progression-free survival of 6.2 months. Median overall survival had not been reached. Pyxis plans to start the Phase 3 Headliner trial in mid-2027, with FDA dose-selection feedback expected in the first quarter of 2027.
Quarter-end cash and investments totaled $57.0 million. An October offering generated approximately $110.0 million in upfront gross proceeds; Pyxis expects quarter-end funds plus net upfront proceeds to support operations into the first half of 2028.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointOctober 1 offering generated approximately $110.0 million in upfront gross proceeds before offering expenses. 55% of market cap
- Moderate pointThird-quarter net loss narrowed to $19.984 million from $22.003 million; loss per share improved to $0.24 from $0.35.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Headliner Phase 3 initiation is planned for mid-2027, following alignment with FDA and EMA design feedback.
- Minor point. Forward-looking: it has not happened yet and may not happen.Pyxis expects existing funds plus net upfront offering proceeds to fund operations into the first half of 2028.
- Minor pointMICVO confirmed response rate was 36% (12/33); disease control rate was 94% (31/33) in efficacy-evaluable patients.
10 minor points
- Minor pointMICVO responders: 75% responded by six weeks; 83% achieved greater than 50% tumor reduction.
- Minor pointMICVO median progression-free survival was 6.2 months (95% confidence interval: 4.8–8.8) in efficacy-evaluable patients.
- Minor pointMICVO 12-month survival probability was 79% (95% confidence interval: 58.1–90.3); median overall survival was not reached.
- Minor pointMICVO safety evaluation found no new safety signals among 35 patients.
- Minor pointMICVO dose capping reduced adverse-event frequency and severity in high body weight patients.
- Minor point. Forward-looking: it has not happened yet and may not happen.Updated MICVO monotherapy overall survival data are expected in the first half of 2027.
- Minor point. Forward-looking: it has not happened yet and may not happen.December combination update is expected to cover at least 20 patients receiving MICVO with pembrolizumab.
- Minor point. Forward-looking: it has not happened yet and may not happen.Combination durability data to inform Phase 3 dose selection are expected in the second half of 2027.
- Minor pointThird-quarter research and development expenses fell to $16.556 million from $17.808 million a year earlier.
- Minor pointThird-quarter general and administrative expenses fell to $3.967 million from $5.653 million a year earlier.
Negative
- Major point. Forward-looking: it has not happened yet and may not happen.Offering included milestone-linked warrants; exercise would dilute holders, and additional proceeds depend on cash exercise.
- Moderate pointFDA feedback on MICVO dose selection remains pending, with an update expected in the first quarter of 2027.
- Moderate pointNine-month net loss widened to $68.602 million from $61.515 million; loss per share improved to $0.98 from $0.99.
- Moderate pointStockholders’ equity declined to $41.320 million at September 30, 2026, from $53.408 million at December 31, 2025.
- Minor pointNine-month milestone revenue fell to zero from $2.820 million a year earlier.
4 minor points
- Minor pointNine-month research and development expenses increased to $52.596 million from $51.985 million a year earlier.
- Minor pointNine-month general and administrative expenses increased to $18.277 million from $16.960 million a year earlier.
- Minor pointInterest and investment income fell to $539,000 quarterly and $1.251 million year-to-date, from $774,000 and $3.010 million.
- Minor pointSublease income fell to zero quarterly and $1.020 million year-to-date, from $684,000 and $1.883 million.
News Explained
The October 1 offering is closed: it generated
Key Figures
- Confirmed objective response rate
- 36% (12/33)
- Phase 1 monotherapy; 5.4 mg/kg dose-cap efficacy-evaluable population
- Disease control rate
- 94% (31/33)
- Phase 1 monotherapy; 5.4 mg/kg dose-cap efficacy-evaluable population
- Median progression-free survival
- 6.2 months
- Phase 1 monotherapy; 95% CI: 4.8–8.8
- 12-month overall survival probability
- 79%
- Phase 1 monotherapy; 95% CI: 58.1–90.3
- Cash and investments
- $57.0 million
- As of September 30, 2026; includes restricted cash and short-term investments
- Operating runway
- Into the first half of 2028
- Company expectation after considering net proceeds from the public offering
- Net loss
- $20.0 million (vs. $22.0 million)
- Quarter ended September 30, 2026, compared with the year-ago quarter
Previous Earnings Reports
-
Q2 loss widened year over year; MICVO monotherapy data were expected in fall 2026.
-
Completed MICVO Phase 1 dose-expansion enrollment and expected updated monotherapy data mid-2026.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
objective response rate medical
disease control rate medical
progression-free survival medical
overall survival medical
antibody-drug conjugate medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Updated Phase 1 monotherapy results in second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma (2L+ R/M HNSCC) showed compelling efficacy data with a manageable safety profile
FDA feedback on dose selection from the End-of-Phase 2 meeting expected in the first quarter of 2027; global Phase 3 HeadlinerSM trial initiation planned for mid-2027
Updated overall survival data from the MICVO Phase 1 monotherapy study expected in the first half of 2027
MICVO Phase 1 monotherapy data in previously treated R/M HNSCC to be presented in a late-breaking oral presentation and preclinical findings to be presented in two posters at the 38th EORTC-NCI-AACR Symposium
December 2026 corporate update to outline MICVO’s development strategy in R/M HNSCC, including updated data from the first-line pembrolizumab combination study
Quarter-end cash and net upfront proceeds from October public offering expected to fund operations into the first half of 2028
BOSTON, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today reported financial results for the quarter ended September 30, 2026, and highlighted continued progress in the development of micvotabart pelidotin (MICVO).
“The September monotherapy data reinforce our confidence in MICVO’s potential to serve a significant population of patients with previously treated recurrent/metastatic head and neck cancer,” said Tom Civik, Chief Executive Officer and Chairman of Pyxis Oncology. “We have aligned with feedback received from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) on the design of the global Phase 3 HeadlinerSM trial and plan to initiate it in mid-2027, with FDA feedback on dose selection expected in the first quarter of 2027. We look forward to presenting MICVO monotherapy data, along with two preclinical posters, at the EORTC-NCI-AACR Symposium in November, and providing a comprehensive update on our head and neck cancer strategy in December, including updated efficacy and safety data from MICVO in combination with pembrolizumab in the first-line setting. Our strengthened balance sheet positions us to execute on these priorities, continue evaluating MICVO’s broader potential and advance toward becoming a pre-commercial organization.”
Pipeline Updates
- Pyxis Oncology has aligned with feedback from the FDA and the EMA on the design of the global pivotal Phase 3 HeadlinerSM trial, which the Company plans to initiate in mid-2027. The randomized, open-label, two-arm trial will evaluate MICVO monotherapy in patients with second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma (2L+ R/M HNSCC) who have progressed following treatment with both platinum-based chemotherapy and an anti-PD-1 therapy. Approximately 500 patients are expected to be randomized 1:1 to receive MICVO or investigator’s choice of cetuximab, docetaxel or methotrexate. The co-primary endpoints are overall response rate and overall survival.
- Pyxis Oncology expects to provide an update in the first quarter of 2027 on FDA feedback regarding dose selection following its End-of-Phase 2 meeting.
- Updated overall survival data from the ongoing MICVO monotherapy study are expected in the first half of 2027.
- Additional data from the Phase 1/2 combination study of MICVO and Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in first-line (1L) R/M HNSCC, including initial durability data to inform selection of the recommended Phase 3 dose, are expected in the second half of 2027.
Reported Updated Phase 1 Monotherapy Data in 2L+ R/M HNSCC
On September 9, 2026, Pyxis Oncology announced updated data from its ongoing global Phase 1 monotherapy study of MICVO in 2L+ R/M HNSCC, as of a data cutoff of August 18, 2026.
In the efficacy-evaluable population receiving MICVO at 5.4 mg/kg intravenously once every three weeks (IV Q3W) at or below a dose cap (N=33):
- Confirmed objective response rate was
36% (12/33), and disease control rate was94% (31/33). - Responses were rapid and deep, with
75% of responders responding by the first scan at six weeks and83% of responders achieving greater than50% tumor reduction. - Median progression-free survival was 6.2 months (
95% CI: 4.8–8.8), and the 12-month overall survival probability was79% (95% CI: 58.1, 90.3). Median overall survival had not yet been reached. - Clinical activity was observed across HPV status and prior-treatment subgroups.
In the safety-evaluable population (N=35), no new safety signals were observed. Dose capping reduced the frequency and severity of adverse events in high body weight patients.
Planned December 2026 Corporate Update
Pyxis Oncology plans to provide a corporate update in December 2026, including:
- A comprehensive development strategy for MICVO in R/M HNSCC, including how emerging combination data inform potential opportunities across treatment settings.
- Updated efficacy and safety data from the ongoing Phase 1/2 combination dose-escalation study evaluating MICVO with KEYTRUDA® (pembrolizumab) across multiple doses in 1L R/M HNSCC.
- The update is expected to include data from a total of at least 20 patients with 1L R/M HNSCC treated with MICVO at the 3.6 mg/kg and 4.4 mg/kg dose levels in combination with a fixed dose of 200 mg of pembrolizumab. Durability data are expected in the second half of 2027.
- The update is expected to include data from a total of at least 20 patients with 1L R/M HNSCC treated with MICVO at the 3.6 mg/kg and 4.4 mg/kg dose levels in combination with a fixed dose of 200 mg of pembrolizumab. Durability data are expected in the second half of 2027.
Corporate Updates
- In September 2026, Pyxis Oncology appointed Tom Civik Chief Executive Officer and Chairman of the Board. Mr. Civik had served as Interim Chief Executive Officer since February 2026 and has been a member of the Board since 2021. John Flavin, co-founder and founding Chairman of Pyxis Oncology, transitioned to Lead Independent Director and continues to serve on the Board.
- On October 1, 2026, Pyxis Oncology closed a registered public offering that generated approximately
$110.0 million in upfront gross proceeds, before deducting underwriting discounts and commissions and other offering expenses. The offering also included milestone-linked warrants that, if exercised in full for cash, would provide approximately$172.6 million in additional gross proceeds, for a total of up to approximately$282.6 million . The Company believes its cash, cash equivalents, restricted cash and short-term investments as of September 30, 2026, together with the net upfront proceeds from the offering, will be sufficient to fund operations into the first half of 2028. Additional details about the offering and accompanying warrants are available in the Company’s October 2, 2026 announcement. - At the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, taking place November 18–20, 2026, in Barcelona, Spain, Phase 1 clinical data for MICVO monotherapy in previously treated R/M HNSCC will be presented by Faye M. Johnson, M.D., Ph.D., of The University of Texas MD Anderson Cancer Center, in a late-breaking oral presentation on November 19. Pyxis Oncology will also present preclinical findings in two poster presentations on November 18, further characterizing MICVO’s extracellular mechanism of action and evaluating MICVO in combination with EGFR-targeted therapy. These findings inform the Company’s broader development strategy for MICVO.
- Tom Civik, Chief Executive Officer and Chairman of the Board, will participate in fireside chats at two upcoming investor conferences. Live webcasts and replays of the fireside chats will be available on the Events & Presentations page in the Investor Relations section of Pyxis Oncology’s website, ir.pyxisoncology.com.
- Guggenheim 3rd Annual Healthcare Innovation Conference: Monday, November 9, 2026, at 9:00 a.m. ET in Boston, MA.
- Stifel 2026 Healthcare Conference: Tuesday, November 10, 2026, at 4:40 p.m. ET in New York, NY.
Third Quarter 2026 Financial Results
- As of September 30, 2026, Pyxis Oncology had cash and cash equivalents, including restricted cash, and short-term investments, of
$57.0 million . After considering net proceeds from the registered public offering, the company believes our cash, cash equivalents, restricted cash and marketable debt securities will be sufficient to fund our operations into the first half of 2028. - Research and development expenses were
$16.6 million for the quarter ended September 30, 2026, compared to$17.8 million for the quarter ended September 30, 2025. The decrease was primarily due to a reduction of$3.6 million in manufacturing costs, partially offset by a$3.0 million increase in clinical trial expenses related to monotherapy and combination therapy of MICVO. - General and administrative expenses were
$4.0 million for the quarter ended September 30, 2026, compared to$5.7 million for the quarter ended September 30, 2025. The decrease was primarily attributable to a$1.4 million decrease in stock-based compensation expense. - Net loss was
$20.0 million , or ($0.24) per common share, for the quarter ended September 30, 2026, compared to$22.0 million , or ($0.35) per common share, for the quarter ended September 30, 2025. The$2.0 million year-over-year decrease in net loss primarily reflected a$1.7 million reduction in non-cash stock-based compensation expense. - As of November 4, 2026, the outstanding number of shares of Common Stock of Pyxis Oncology was 119,607,855.
About Micvotabart Pelidotin (MICVO)
Micvotabart pelidotin (MICVO, formerly PYX-201) is an investigational antibody-drug conjugate (ADC) that uniquely targets extradomain-B of fibronectin (EDB+FN), a non-cellular structural component of the tumor extracellular matrix. MICVO is designed to generate a multi-pronged attack on difficult-to-treat cancers by directly killing cancer cells, reducing extracellular matrix density, inhibiting tumor angiogenesis and mobilizing an anti-tumor immune response.
MICVO received Fast Track Designation from the U.S. Food and Drug Administration for the treatment of adult patients with R/M HNSCC whose disease has progressed following treatment with platinum-based chemotherapy and an anti-PD-(L)1 therapy.
About Pyxis Oncology
Pyxis Oncology, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for difficult-to-treat cancers. The Company’s lead candidate, micvotabart pelidotin (MICVO), is a first-in-concept antibody-drug conjugate (ADC) that targets extradomain-B of fibronectin (EDB+FN), a non-cellular structural component of the tumor extracellular matrix (ECM). EDB+FN is selectively overexpressed in the tumor microenvironment of a wide range of solid tumors and largely absent from normal adult tissues. MICVO is designed to treat solid tumors through a three-pronged mechanism of action: direct cancer cell killing, bystander effect and immunogenic cell death. MICVO is currently being evaluated as monotherapy in a Phase 1 clinical study in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) and in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in a Phase 1/2 clinical study in patients with R/M HNSCC and other solid tumors. Pyxis Oncology is focused on advancing MICVO, with the goal of improving outcomes for patients living with R/M HNSCC and contributing to meaningful progress in cancer treatment.
To learn more, visit www.pyxisoncology.com or follow us on LinkedIn.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Forward-Looking Statements
This press release contains forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws. These statements are often identified by the use of words such as “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “likely,” “may,” “might,” “objective,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “to be,” “will,” “would,” or the negative or plural of these words, or similar expressions or variations, although not all forward-looking statements contain these words. We cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur and actual results could differ materially from those expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified herein, and those discussed in the section titled “Risk Factors” set forth in Part II, Item 1A. of the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 5, 2026, and our other filings, each of which is on file with the SEC. These risks are not exhaustive. New risk factors emerge from time to time, and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date hereof, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.
Pyxis Oncology Contact
IR@pyxisoncology.com
| PYXIS ONCOLOGY, INC. Condensed Consolidated Statements of Operations and Comprehensive Loss (In thousands, except share and per share amounts) (Unaudited) | ||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Milestone revenue | $ | — | $ | — | $ | — | $ | 2,820 | ||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 16,556 | 17,808 | 52,596 | 51,985 | ||||||||||||
| General and administrative | 3,967 | 5,653 | 18,277 | 16,960 | ||||||||||||
| Total operating expenses | 20,523 | 23,461 | 70,873 | 68,945 | ||||||||||||
| Loss from operations | (20,523 | ) | (23,461 | ) | (70,873 | ) | (66,125 | ) | ||||||||
| Other income, net: | ||||||||||||||||
| Interest and investment income, net | 539 | 774 | 1,251 | 3,010 | ||||||||||||
| Sublease income | — | 684 | 1,020 | 1,883 | ||||||||||||
| Total other income, net | 539 | 1,458 | 2,271 | 4,893 | ||||||||||||
| Loss before income taxes | (19,984 | ) | (22,003 | ) | (68,602 | ) | (61,232 | ) | ||||||||
| Income tax expense | — | — | — | 283 | ||||||||||||
| Net loss | $ | (19,984 | ) | $ | (22,003 | ) | $ | (68,602 | ) | $ | (61,515 | ) | ||||
| Net loss per common share - basic and diluted | $ | (0.24 | ) | $ | (0.35 | ) | $ | (0.98 | ) | $ | (0.99 | ) | ||||
| Weighted average shares of common stock outstanding - basic and diluted | 83,508,174 | 62,557,386 | 70,149,530 | 61,847,245 | ||||||||||||
| PYXIS ONCOLOGY, INC. Condensed Consolidated Balance Sheets (In thousands, except share and per share amounts) (Unaudited) | ||||||||
| September 30, 2026 | December 31, 2025 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 3,856 | $ | 15,422 | ||||
| Marketable debt securities | 51,716 | 51,435 | ||||||
| Restricted cash | 1,472 | 1,472 | ||||||
| Prepaid expenses and other current assets | 2,083 | 3,776 | ||||||
| Total current assets | 59,127 | 72,105 | ||||||
| Property and equipment, net | 6,939 | 7,997 | ||||||
| Operating lease right-of-use asset | 10,704 | 11,418 | ||||||
| Total assets | $ | 76,770 | $ | 91,520 | ||||
| Liabilities and Stockholders’ Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 8,124 | $ | 10,885 | ||||
| Accrued expenses and other current liabilities | 9,926 | 8,554 | ||||||
| Operating lease liabilities, current portion | 1,892 | 1,692 | ||||||
| Total current liabilities | 19,942 | 21,131 | ||||||
| Operating lease liabilities, net of current portion | 15,508 | 16,958 | ||||||
| Financing lease liabilities, net of current portion | — | 23 | ||||||
| Total liabilities | 35,450 | 38,112 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ equity: | ||||||||
| Preferred stock | — | — | ||||||
| Common stock | 83 | 63 | ||||||
| Additional paid-in capital | 553,072 | 496,469 | ||||||
| Accumulated other comprehensive (loss) income | (56 | ) | 53 | |||||
| Accumulated deficit | (511,779 | ) | (443,177 | ) | ||||
| Total stockholders’ equity | 41,320 | 53,408 | ||||||
| Total liabilities and stockholders’ equity | $ | 76,770 | $ | 91,520 | ||||
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Pyxis Oncology’s MICVO Phase 1 head and neck cancer study show?
MICVO produced a 36% confirmed objective response rate (12/33) in the efficacy-evaluable population receiving 5.4 mg/kg intravenously every three weeks at or below a dose cap. At the August 18, 2026 data cutoff, median progression-free survival was 6.2 months and median overall survival had not been reached.
How long does Pyxis Oncology expect its cash to last after the October offering?
Pyxis expects its quarter-end funds plus net upfront offering proceeds to fund operations into the first half of 2028. Cash, cash equivalents, restricted cash and short-term investments totaled $57.0 million at September 30, 2026. The offering closed October 1, 2026, generating approximately $110.0 million in upfront gross proceeds before offering expenses.
How will Pyxis Oncology’s Phase 3 Headliner trial test MICVO?
The planned Headliner trial will compare MICVO monotherapy with investigator’s choice of cetuximab, docetaxel or methotrexate. Approximately 500 patients are expected to be randomized 1:1 in the open-label study. Eligible patients will have recurrent/metastatic head and neck squamous cell carcinoma that progressed after platinum-based chemotherapy and anti-PD-1 therapy. The co-primary endpoints are overall response rate and overall survival.
Which MICVO doses will Pyxis Oncology cover in its December 2026 combination update?
The planned update will cover 3.6 mg/kg and 4.4 mg/kg MICVO, each combined with a fixed 200 mg dose of pembrolizumab. Pyxis expects updated efficacy and safety data from the ongoing Phase 1/2 dose-escalation study in first-line recurrent/metastatic head and neck squamous cell carcinoma.